FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Nanoparticulate CpG immunotherapy in RAO-affected horses: ph...
Journal of veterinary internal medicine2015; 29(1); 286-293; doi: 10.1111/jvim.12524

Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study.

Abstract: Recurrent airway obstruction (RAO), an asthma-like disease, is 1 of the most common allergic diseases in horses in the northern hemisphere. Hypersensitivity reactions to environmental antigens cause an allergic inflammatory response in the equine airways. Cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODN) are known to direct the immune system toward a Th1-pathway, and away from the pro-allergic Th2-line (Th2/Th1-shift). Gelatin nanoparticles (GNPs) are biocompatible and biodegradable immunological inert drug delivery systems that protect CpG-ODN against nuclease degeneration. Preliminary studies on the inhalation of GNP-bound CpG-ODN in RAO-affected horses have shown promising results. Objective: The aim of this study was to evaluate the clinical and immunological effects of GNP-bound CpG-ODN in a double-blinded, placebo-controlled, prospective, randomized clinical trial and to verify a sustained effect post-treatment. Methods: Twenty-four RAO-affected horses received 1 inhalation every 2 days for 5 consecutive administrations. Horses were examined for clinical, endoscopic, cytological, and blood biochemical variables before the inhalation regimen (I), immediately afterwards (II), and 4 weeks post-treatment (III). Results: At time points I and II, administration of treatment rather than placebo corresponded to a statistically significant decrease in respiratory effort, nasal discharge, tracheal secretion, and viscosity, AaDO2 and neutrophil percentage, and an increase in arterial oxygen pressure. Conclusions: Administration of a GNP-bound CpG-ODN formulation caused a potent and persistent effect on allergic and inflammatory-induced clinical variables in RAO-affected horses. This treatment, therefore, provides an innovative, promising, and well-tolerated strategy beyond conventional symptomatic long-term therapy and could serve as a model for asthma treatment in humans.
Copyright © 2015 by the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2015-01-27 PubMed ID: 25619520PubMed Central: PMC4858074DOI: 10.1111/jvim.12524Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Phase I
  • Clinical Trial
  • Phase II
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the use of Gelatin Nanoparticles (GNP) loaded with Cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODN) to rebalance the immune response in horses affected by Recurrent Airway Obstruction (RAO). The preliminary results show reduced respiratory symptoms in the horses, promising a potential new treatment approach for RAO and, possibly, human asthma.

Introduction and Objective

  • The paper explores the use of CpG-ODN, substances known to stimulate the Th1-pathway of the immune system, encapsulated in Gelatin Nanoparticles (GNP). This approach aims to shift the immune response from a pro-allergic Th2-line (which typically characterizes RAO) to a Th1-pathway (less associated with allergic reactions).
  • The goal of the study was to evaluate the clinical and immunological effects of the GNP-bound CpG-ODN on horses suffering from RAO. The researchers also aimed to verify whether these effects were sustained over time.

Methods

  • Twenty-four RAO-affected horses participated in this double-blinded, placebo-controlled, randomized clinical trial.
  • The horses received an inhalation of GNP-bound CpG-ODN every two days for five consecutive days. Their clinical and immunological status was evaluated before the treatment (I), immediately afterwards (II), and four weeks after the treatment ended (III).

Results

  • The study found significant improvements in treated horses at times I and II, with a decrease in respiratory effort, nasal discharge, tracheal secretion, viscosity, AaDO2 (which measures oxygen diffusion efficiency), and neutrophil percentage (indicating decreased inflammation).
  • An increase in arterial oxygen pressure was also observed, indicating better oxygen supply.

Conclusions

  • The use of GNP-bound CpG-ODN has shown potent and lasting effects on RAO symptoms, making it a potentially promising and novel treatment strategy.
  • Due to the asthma-like nature of RAO, this research could inspire groundbreaking strategies for human asthma treatment as well.

Cite This Article

APA
Klier J, Lehmann B, Fuchs S, Reese S, Hirschmann A, Coester C, Winter G, Gehlen H. (2015). Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study. J Vet Intern Med, 29(1), 286-293. https://doi.org/10.1111/jvim.12524

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 29
Issue: 1
Pages: 286-293

Researcher Affiliations

Klier, J
  • Centre for Clinical Veterinary Medicine, Equine Clinic, Ludwig Maximilians University, Munich, Germany.
Lehmann, B
    Fuchs, S
      Reese, S
        Hirschmann, A
          Coester, C
            Winter, G
              Gehlen, H

                MeSH Terms

                • Animals
                • Auscultation
                • Female
                • Horse Diseases / drug therapy
                • Horses
                • Lung / pathology
                • Lung Diseases, Obstructive / drug therapy
                • Lung Diseases, Obstructive / veterinary
                • Male
                • Mucus
                • Nanoparticles / adverse effects
                • Nanoparticles / therapeutic use
                • Oligodeoxyribonucleotides / adverse effects
                • Oligodeoxyribonucleotides / therapeutic use
                • Oxygen / blood
                • Partial Pressure
                • Respiration / drug effects

                References

                This article includes 35 references
                1. Robinson NE. Recurrent airway obstruction (Heaves). .
                2. Neuhaus S, Bruendler P, Frey CF, Gottstein B, Doherr MG, Gerber V. Increased parasite resistance and recurrent airway obstruction in horses of a high-prevalence family.. J Vet Intern Med 2010 Mar-Apr;24(2):407-13.
                  pubmed: 20102498doi: 10.1111/j.1939-1676.2009.0465.xgoogle scholar: lookup
                3. Lunn P, Horohov D. The equine immune system. .
                4. Kirschvink N, Reinhold P. Use of alternative animals as asthma models.. Curr Drug Targets 2008 Jun;9(6):470-84.
                  pubmed: 18537586doi: 10.2174/138945008784533525google scholar: lookup
                5. Millerick-May ML, Karmaus W, Derksen FJ, Berthold B, Holcombe SJ, Robinson NE. Particle mapping in stables at an American Thoroughbred racetrack.. Equine Vet J 2011 Sep;43(5):599-607.
                  pubmed: 21496092doi: 10.1111/j.2042-3306.2010.00331.xgoogle scholar: lookup
                6. Gerber V, Baleri D, Klukowska-Rötzler J, Swinburne JE, Dolf G. Mixed inheritance of equine recurrent airway obstruction.. J Vet Intern Med 2009 May-Jun;23(3):626-30.
                  pubmed: 19645845doi: 10.1111/j.1939-1676.2009.0292.xgoogle scholar: lookup
                7. Künzle F, Gerber V, Van Der Haegen A, Wampfler B, Straub R, Marti E. IgE-bearing cells in bronchoalveolar lavage fluid and allergen-specific IgE levels in sera from RAO-affected horses.. J Vet Med A Physiol Pathol Clin Med 2007 Feb;54(1):40-7.
                  pubmed: 17359454doi: 10.1111/j.1439-0442.2007.00870.xgoogle scholar: lookup
                8. Ainsworth DM, Cheetham J. Disorders of the respiratory system. .
                9. Moran G, Folch H. Recurrent airway obstruction in horses—An allergic inflammation: A review. Vet Med ‐ Czech 2011;56:1–13.
                10. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease.. Adv Drug Deliv Rev 2009 Mar 28;61(3):256-62.
                  pubmed: 19167442doi: 10.1016/j.addr.2008.12.007google scholar: lookup
                11. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.. Adv Drug Deliv Rev 2009 Mar 28;61(3):195-204.
                  pubmed: 19211030doi: 10.1016/j.addr.2008.12.008google scholar: lookup
                12. Schneberger D, Caldwell S, Suri SS, Singh B. Expression of toll-like receptor 9 in horse lungs.. Anat Rec (Hoboken) 2009 Jul;292(7):1068-77.
                  pubmed: 19548205doi: 10.1002/ar.20927google scholar: lookup
                13. Wilson KD, de Jong SD, Tam YK. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.. Adv Drug Deliv Rev 2009 Mar 28;61(3):233-42.
                  pubmed: 19232375doi: 10.1016/j.addr.2008.12.014google scholar: lookup
                14. Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S, Winter G, Coester C, Endres S. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.. J Immunol 2008 Sep 1;181(5):2990-8.
                  pubmed: 18713969doi: 10.4049/jimmunol.181.5.2990google scholar: lookup
                15. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.. Pharm Res 2008 Mar;25(3):551-62.
                  pubmed: 17912489doi: 10.1007/s11095-007-9410-5google scholar: lookup
                16. Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt Cv. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.. Biochem Biophys Res Commun 2004 May 28;318(2):562-70.
                  pubmed: 15120637doi: 10.1016/j.bbrc.2004.04.067google scholar: lookup
                17. Tseng CL, Wu SY, Wang WH, Peng CL, Lin FH, Lin CC, Young TH, Shieh MJ. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer.. Biomaterials 2008 Jul;29(20):3014-22.
                  pubmed: 18436301doi: 10.1016/j.biomaterials.2008.03.033google scholar: lookup
                18. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.. Biomaterials 2009 Jul;30(20):3476-85.
                  pubmed: 19345990doi: 10.1016/j.biomaterials.2009.03.010google scholar: lookup
                19. Fuchs S, Klier J, May A, Winter G, Coester C, Gehlen H. Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies.. J Microencapsul 2012;29(7):615-25.
                  pubmed: 22432849doi: 10.3109/02652048.2012.668962google scholar: lookup
                20. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kündig TM. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.. Clin Exp Allergy 2009 Apr;39(4):562-70.
                  pubmed: 19226280doi: 10.1111/j.1365-2222.2008.03191.xgoogle scholar: lookup
                21. Mueller RS, Veir J, Fieseler KV, Dow SW. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study.. Vet Dermatol 2005 Feb;16(1):61-8.
                  pubmed: 15725107doi: 10.1111/j.1365-3164.2005.00426.xgoogle scholar: lookup
                22. Hullmann AG. Prophylaxe der Rhodococcus equi‐Pneumonie bei Fohlen durch Vakzination mit Rhodococcus equi‐Impfstoff und Adjuvans CpG XXXX. School of Veterinary Medicine Hannover; 2006. Thesis.
                23. Lopez AM, Hecker R, Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA, Townsend HG. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine.. Vet Immunol Immunopathol 2006 Nov 15;114(1-2):103-10.
                  pubmed: 16950519doi: 10.1016/j.vetimm.2006.07.013google scholar: lookup
                24. Liu T, Nerren J, Murrell J. CpG‐induced stimulation of cytokine expression by peripheral blood mononuclear cells of foals and their dams. J Jevs 2008;28:419–426.
                25. Liu T, Nerren J, Liu M, Martens R, Cohen N. Basal and stimulus-induced cytokine expression is selectively impaired in peripheral blood mononuclear cells of newborn foals.. Vaccine 2009 Jan 29;27(5):674-83.
                  pubmed: 19056444doi: 10.1016/j.vaccine.2008.11.040google scholar: lookup
                26. Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.. Pharm Res 2012 Jun;29(6):1650-7.
                  pubmed: 22302522doi: 10.1007/s11095-012-0686-8google scholar: lookup
                27. Robinson NE. International Workshop on Equine Chronic Airway Disease. Michigan State University 16-18 June 2000.. Equine Vet J 2001 Jan;33(1):5-19.
                  pubmed: 11191611doi: 10.2746/042516401776767412google scholar: lookup
                28. Gerber V, King M, Schneider DA, Robinson NE. Tracheobronchial mucus viscoelasticity during environmental challenge in horses with recurrent airway obstruction.. Equine Vet J 2000 Sep;32(5):411-7.
                  pubmed: 11037263doi: 10.2746/042516400777591183google scholar: lookup
                29. Grabner A. Arterielle Blutgasanalyse. In: Kraft W, Dürr UM, eds. Klinische Labordiagnostik in der Tiermedizin, 6th ed Stuttgart: Schattauer; 2005:429–430.
                30. Gerber V, Straub R, Marti E, Hauptman J, Herholz C, King M, Imhof A, Tahon L, Robinson NE. Endoscopic scoring of mucus quantity and quality: observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume.. Equine Vet J 2004 Nov;36(7):576-82.
                  pubmed: 15581321doi: 10.2746/0425164044864525google scholar: lookup
                31. Deegen E, Klein HJ. Interpleuraldruckmessungen und Bronchospasmolysetests mit einem portalen Ösophagusdruckmessgerät. Pferdeheilkunde 1987;21:213–221.
                32. Klier J, May A, Fuchs S, Schillinger U, Plank C, Winter G, Gehlen H, Coester C. Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles.. Vet Immunol Immunopathol 2011 Nov 15;144(1-2):79-87.
                  pubmed: 21831455doi: 10.1016/j.vetimm.2011.07.009google scholar: lookup
                33. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.. J Control Release 2004 May 31;97(1):1-17.
                  pubmed: 15147800doi: 10.1016/j.jconrel.2004.02.022google scholar: lookup
                34. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists.. Biol Rev Camb Philos Soc 2007 Nov;82(4):591-605.
                  pubmed: 17944619doi: 10.1111/j.1469-185x.2007.00027.xgoogle scholar: lookup
                35. Klier J. Neuer Therapieansatz zur Behandlung der COB des Pferdes durch Immunstimulation von BAL‐Zellen mit verschiedenen CpG‐Klassen. Munich: School of Veterinary Medicine, Ludwig‐Maximilians University; 2011. Thesis.

                Citations

                This article has been cited 10 times.
                1. Klier J, Fuchs S, Winter G, Gehlen H. Inhalative Nanoparticulate CpG Immunotherapy in Severe Equine Asthma: An Innovative Therapeutic Concept and Potential Animal Model for Human Asthma Treatment. Animals (Basel) 2022 Aug 16;12(16).
                  doi: 10.3390/ani12162087pubmed: 36009677google scholar: lookup
                2. Davis KU, Sheats MK. Differential gene expression and Ingenuity Pathway Analysis of bronchoalveolar lavage cells from horses with mild/moderate neutrophilic or mastocytic inflammation on BAL cytology. Vet Immunol Immunopathol 2021 Apr;234:110195.
                  doi: 10.1016/j.vetimm.2021.110195pubmed: 33588285google scholar: lookup
                3. Reddy PRK, Yasaswini D, Reddy PPR, Zeineldin M, Adegbeye MJ, Hyder I. Applications, challenges, and strategies in the use of nanoparticles as feed additives in equine nutrition. Vet World 2020 Aug;13(8):1685-1696.
                  doi: 10.14202/vetworld.2020.1685-1696pubmed: 33061246google scholar: lookup
                4. Pali-Schöll I, DeBoer DJ, Alessandri C, Seida AA, Mueller RS, Jensen-Jarolim E. Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon. Front Immunol 2020;11:1697.
                  doi: 10.3389/fimmu.2020.01697pubmed: 32849594google scholar: lookup
                5. Barton AK, Shety T, Klier J, Geis S, Einspanier R, Gehlen H. Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma. Mediators Inflamm 2019;2019:7845623.
                  doi: 10.1155/2019/7845623pubmed: 31316303google scholar: lookup
                6. Klier J, Bartl C, Geuder S, Geh KJ, Reese S, Goehring LS, Winter G, Gehlen H. Immunomodulatory asthma therapy in the equine animal model: A dose-response study and evaluation of a long-term effect. Immun Inflamm Dis 2019 Sep;7(3):130-149.
                  doi: 10.1002/iid3.252pubmed: 31141308google scholar: lookup
                7. Bond S, Léguillette R, Richard EA, Couetil L, Lavoie JP, Martin JG, Pirie RS. Equine asthma: Integrative biologic relevance of a recently proposed nomenclature. J Vet Intern Med 2018 Nov;32(6):2088-2098.
                  doi: 10.1111/jvim.15302pubmed: 30294851google scholar: lookup
                8. Klier J, Geis S, Steuer J, Geh K, Reese S, Fuchs S, Mueller RS, Winter G, Gehlen H. A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma-affected horses, an animal model. Immun Inflamm Dis 2018 Mar;6(1):81-96.
                  doi: 10.1002/iid3.198pubmed: 29094511google scholar: lookup
                9. Couëtil LL, Cardwell JM, Gerber V, Lavoie JP, Léguillette R, Richard EA. Inflammatory Airway Disease of Horses--Revised Consensus Statement. J Vet Intern Med 2016 Mar-Apr;30(2):503-15.
                  doi: 10.1111/jvim.13824pubmed: 26806374google scholar: lookup
                10. Herrmann I, Sanchez AJ. Efficacy and Safety of Subcutaneous Allergen-Specific Immuno-Therapy in Horses with Allergic Cutaneous and Respiratory Diseases-A Systematic Review. Vet Sci 2023 Oct 10;10(10).
                  doi: 10.3390/vetsci10100613pubmed: 37888565google scholar: lookup
                Subscribe to our newsletter
                Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.